A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension

被引:0
|
作者
Godfrey, David A. [1 ]
Peplinski, Lee S. [2 ]
Stewart, Jeanette A. [3 ]
Stewart, William C. [3 ]
机构
[1] Glaucoma Associates Texas, Dallas, TX USA
[2] Kentuckiana Inst Eye Res, Louisville, KY USA
[3] PRN Pharmaceut Res Network LLC, 5001 LBJ Freeway,Suite 700, Dallas, TX 75244 USA
来源
CLINICAL OPHTHALMOLOGY | 2009年 / 3卷
关键词
comfort; travoprost BAK-free; latanoprost; glaucoma; ocular hypertension;
D O I
暂无
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the short-term comfort after a single dose of travoprost BAK-free compared to latanoprost in primary open-angle glaucoma or ocular hypertensive patients. Design: Prospective, double-masked, randomized comparison of two separate active agents dosed once in opposite eyes. Methods: At Visit 1, qualified patients began a glaucoma medicine-free period for three days. At Visit 2, patients were randomly assigned to travoprost BAK-free or latanoprost in opposite eyes. Following dosing in each eye, patients completed a visual analog scale (VAS score, 0-100 mm) at specified time intervals and a comfort survey. Results: In 54 completed subjects, no difference existed five seconds after dosing, in comfort on the VAS between latanoprost (7.1 +/- 16.2 mm) and travoprost BAK-free (7.8 +/- 16.1 mm, P = 0.53). Also no differences existed between treatments following dosing for discomfort at individual timepoints past five seconds, peak discomfort or the time required to return to baseline comfort (P +/- 0.05). In addition, the comfort survey demonstrated no difference between products for burning, stinging, foreign body sensation, overall comfort and general acceptance between the products, both for absolute levels and changes from baseline (P +/- 0.05). Conclusion: Following a single instillation, both latanoprost and travoprost BAK-free exhibit similar comfort scores.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 50 条
  • [21] Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension
    Netland, PA
    Robertson, SM
    Sullivan, EK
    Silver, L
    Bergamini, MVW
    Krueger, S
    Weiner, AL
    Davis, AA
    ADVANCES IN THERAPY, 2003, 20 (03) : 149 - 163
  • [22] A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension
    Topouzis, F.
    Melamed, S.
    Danesh-Meyer, H.
    Wells, A. P.
    Kozobolis, V.
    Wieland, H.
    Andrew, R.
    Wells, D.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2007, 17 (02) : 183 - 190
  • [23] Long-term Effect of BAK-free Travoprost on Ocular Surface and Intraocular Pressure in Glaucoma Patients After Transition From Latanoprost
    Aihara, Makoto
    Otani, Shin-ichiro
    Kozaki, Jun
    Unoki, Kazuhiko
    Takeuchi, Masamitsu
    Minami, Keiichiro
    Miyata, Kazunori
    JOURNAL OF GLAUCOMA, 2012, 21 (01) : 60 - 64
  • [24] Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis
    Yang, Xi-Ting
    Zhao, Lin
    Wang, Li-Jun
    Zhong, Yi
    Liao, Ding-Ying
    Wang, Jian-Ming
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2020, 13 (03) : 474 - 480
  • [25] Comparison of latanoprost monotherapy with timolol-dorzolamide combination in patients with open-angle glaucoma or ocular hypertension
    Bron, A
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2002, 25 (06): : 604 - 608
  • [26] Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
    Schnober, Dietmar
    Hofmann, Gunter
    Maier, Hubert
    Scherzer, Maria-Luise
    Ogundele, Abayomi B.
    Jasek, Mark C.
    CLINICAL OPHTHALMOLOGY, 2010, 4 : 1459 - 1463
  • [27] Comparison of the Efficacy and Safety of Fixed Combination Travoprost/Timolol and Dorzolamide/Timolol in Patients with Primary Open-Angle Glaucoma and Ocular Hypertension
    Babic, Nikola
    Andreic, Veljko
    Miljkovic, Aleksandar
    Grkovic, Desanka
    Jovanovic, Predrag
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2013, 141 (7-8) : 441 - 446
  • [28] Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis
    Xi-Ting Yang
    Lin Zhao
    Li-Jun Wang
    Yi Zhang
    Ding-Ying Liao
    Jian-Ming Wang
    International Journal of Ophthalmology, 2020, (03) : 474 - 480
  • [29] Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension
    Kaluzny, Jozef
    Sobecki, Roman
    Czechowicz-Janicka, Krystyna
    Kecik, Dariusz
    Kaluzny, Bartlomiej J.
    Stewart, Jeanette A.
    Stewart, William C.
    ACTA OPHTHALMOLOGICA, 2008, 86 (08) : 860 - 865
  • [30] Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension
    Aptel, Florent
    Pfeiffer, Norbert
    Schmickler, Stefanie
    Clarke, Jonathan
    Lavin-Dapena, Cosme
    Moreno-Montanes, Javier
    Zarnowski, Tomasz
    Csutak, Adrienne
    Jugaste, Tiia
    Volksone, Lasma
    Astakhov, Yury S.
    Coupier, Laurent
    Nordmann, Jean-Philippe
    Stalmans, Ingeborg
    JOURNAL OF GLAUCOMA, 2019, 28 (06) : 498 - 506